JP2016512504A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512504A5
JP2016512504A5 JP2016500921A JP2016500921A JP2016512504A5 JP 2016512504 A5 JP2016512504 A5 JP 2016512504A5 JP 2016500921 A JP2016500921 A JP 2016500921A JP 2016500921 A JP2016500921 A JP 2016500921A JP 2016512504 A5 JP2016512504 A5 JP 2016512504A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
phenyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512504A (ja
JP6386527B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/022238 external-priority patent/WO2014143607A1/en
Publication of JP2016512504A publication Critical patent/JP2016512504A/ja
Publication of JP2016512504A5 publication Critical patent/JP2016512504A5/ja
Application granted granted Critical
Publication of JP6386527B2 publication Critical patent/JP6386527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500921A 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロピリダジン Expired - Fee Related JP6386527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775742P 2013-03-11 2013-03-11
US61/775,742 2013-03-11
PCT/US2014/022238 WO2014143607A1 (en) 2013-03-11 2014-03-10 Pyrrolopyridazines as potassium ion channel inhibitors

Publications (3)

Publication Number Publication Date
JP2016512504A JP2016512504A (ja) 2016-04-28
JP2016512504A5 true JP2016512504A5 (enExample) 2017-04-13
JP6386527B2 JP6386527B2 (ja) 2018-09-05

Family

ID=50382739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500921A Expired - Fee Related JP6386527B2 (ja) 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロピリダジン

Country Status (6)

Country Link
US (1) US9458164B2 (enExample)
EP (1) EP2970295B1 (enExample)
JP (1) JP6386527B2 (enExample)
CN (1) CN105008366B (enExample)
ES (1) ES2616026T3 (enExample)
WO (1) WO2014143607A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
EP2970294B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
BR112020015444A2 (pt) * 2018-01-30 2020-12-08 Buckman Laboratories International, Inc Método para controlar o crescimento de pelo menos um microrganismo em um produto, método para controlar o crescimento de pelo menos um microrganismo contaminante em um estoque de abastecimento contendo carboidrato fermentável, método para produzir etanol por fermentação com crescimento controlado de microrganismos contaminantes e solução aquosa
WO2024155846A1 (en) * 2023-01-19 2024-07-25 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
CN121464139A (zh) 2023-07-05 2026-02-03 巴斯夫欧洲公司 用于对抗植物病原性真菌的取代的喹啉基/喹喔啉基二氢吡咯并三嗪化合物
WO2025008227A1 (en) 2023-07-05 2025-01-09 Basf Se Substituted pyridyl/pyrazinyl dihydropyrrolotriazine compounds for combatting phytopath-ogenic fungi
CN121941688A (zh) * 2023-10-09 2026-04-28 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途
WO2026019918A1 (en) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
KR100847605B1 (ko) * 2000-11-17 2008-07-21 브리스톨-마이어스스퀴브컴파니 p38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MXPA05011993A (es) * 2003-05-07 2006-02-02 Pharmacia & Upjohn Co Llc Compuestos de pirrolo[1,2-b]piridazina.
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2134716A1 (en) * 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2400604T3 (es) 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
AR077428A1 (es) 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
ES2900504T3 (es) 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
EP2623505B1 (en) 2010-09-29 2015-07-29 Kissei Pharmaceutical Co., Ltd. (aza)indolizine derivatives as xanthine oxidase inhibitors
US8921368B2 (en) * 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
US8987268B2 (en) * 2011-03-17 2015-03-24 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
AR085436A1 (es) * 2011-03-17 2013-10-02 Bristol Myers Squibb Co Derivados de pirrolopiridazina inhibidores de jak3, composiciones farmaceuticas que los contienen y su uso para tratar enfermedades inflamatorias y autoinmunes
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
AU2013274619B2 (en) * 2012-06-11 2017-09-28 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
EP2970294B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors

Similar Documents

Publication Publication Date Title
JP2016512505A5 (enExample)
JP2016514129A5 (enExample)
JP2016516691A5 (enExample)
JP2019034943A5 (enExample)
JP2021527125A5 (enExample)
JP2019094345A5 (enExample)
JP2012532112A5 (enExample)
JP2015500843A5 (enExample)
JP2015145426A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2015500223A5 (enExample)
JP2018524390A5 (enExample)
JP2016531126A5 (enExample)
JP2014015465A5 (enExample)
JP2014037426A5 (enExample)
JP2017526727A5 (enExample)
JP2018537535A5 (enExample)
JP2016517417A5 (enExample)
JP2017517538A5 (enExample)
JP2013527847A5 (enExample)
JP2016510326A5 (enExample)
JP2016528273A5 (enExample)
PH12018500765B1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
JP2017537937A5 (enExample)
JP2018525430A5 (enExample)